doripenem
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
pharma · Ventilator-Associated Pneumonia · Carcinoma, Squamous Cell
Janssen Research &
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen Research & drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Raritan, USA HQ
2001 Founded
95 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Raritan, USA
- Founded
- 2001
- Employees
- 95
- Programs
- 0
- Drugs
- 3
- Patents
- 0
Janssen Research & pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Janssen Research & drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
rivaroxaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
trabectedin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor